Al Sebayel Mohammed I, Elsiesy Hussien, Al-Hamoudi Waleed, Alabbad Saleh, ElSheikh Yasser, Elbeshbeshy Hany, Salih Isam, Yousif Sarra, Saleh Yahia, Eldali Abdulmoneim, Abaalkhail Faisal A
Department of Liver & Small Bowel Transplantation and Hepatobiliary-Pancreatic Surgery, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Exp Clin Transplant. 2017 Mar;15(Suppl 2):7-11. doi: 10.6002/ect.TOND16.L4.
Hepatocellular carcinoma is among the leading causes of cancer death. The Milan criteria are the first and most widely used criteria for selecting patients with hepatocellular carcinoma for a good transplant outcome. Studies have shown that patients with hepatocellular carcinoma outside the Milan criteria have good outcomes if they are successfully downstaged before transplant. We report our experience with locoregional therapy for hepatocellular carcinoma, either for bridging or for downstaging prior to transplant.
We retrospectively reviewed the electronic charts and our institutional database for adult patients diagnosed with hepatocellular carcinoma between 2001 and 2016. We recorded patient demographics, the type of transplant (living donor or deceased donor), radiologic findings, the type of locoregional intervention, and overall survival.
A total of 642 adult liver transplants were performed during the study period (290 living donor and 352 deceased donor), of which 158 (24.6%) were conducted in patients with hepatocellular carcinoma (104 men and 54 women). Hepatocellular carcinoma was associated with hepatitis C in 80 patients (51%), hepatitis B in 44 (28%), and was cryptogenic in 13 (8%). Patients were grouped based on their radiologic staging (within Milan, within and beyond University of California, San Francisco), and subsequently described by whether they received locoregional therapy. Median survival and mortality were noted. Kaplan-Meier survival curves showed no statistically significant difference for patients within the Milan criteria, with or without locoregional therapy (P = .5). When patients within the Milan criteria were combined with patients within the University of California, San Francisco criteria, those who were downstaged from outside the latter criteria had similar survival.
We demonstrate that carefully selected patients beyond the Milan criteria and even beyond the University of California, San Francisco criteria can be bridged and downstaged successfully for liver transplant.
肝细胞癌是癌症死亡的主要原因之一。米兰标准是首个且最广泛应用于选择肝细胞癌患者以获得良好移植结局的标准。研究表明,不符合米兰标准的肝细胞癌患者若在移植前成功降期,其结局良好。我们报告我们在肝细胞癌局部区域治疗方面的经验,该治疗用于移植前的桥接或降期。
我们回顾性分析了2001年至2016年间诊断为肝细胞癌的成年患者的电子病历和我们机构的数据库。我们记录了患者的人口统计学信息、移植类型(活体供体或尸体供体)、影像学检查结果、局部区域干预类型以及总生存期。
在研究期间共进行了642例成人肝移植(290例活体供体和352例尸体供体),其中158例(24.6%)是为肝细胞癌患者进行的(104例男性和54例女性)。80例(51%)肝细胞癌患者与丙型肝炎相关,44例(28%)与乙型肝炎相关,13例(8%)病因不明。患者根据其影像学分期(符合米兰标准、符合及超出加利福尼亚大学旧金山分校标准)进行分组,随后按是否接受局部区域治疗进行描述。记录了中位生存期和死亡率。Kaplan-Meier生存曲线显示,符合米兰标准的患者,无论是否接受局部区域治疗,差异均无统计学意义(P = 0.5)。当将符合米兰标准的患者与符合加利福尼亚大学旧金山分校标准的患者合并时,那些从后者标准范围外降期的患者生存期相似。
我们证明,精心挑选的不符合米兰标准甚至超出加利福尼亚大学旧金山分校标准的患者可以成功地进行桥接和降期以接受肝移植。